-
ASCO Highlights | Professor Yijun Shen: Dual Frontiers in Urologic Oncology Move Earlier as Chinese-Developed Immunotherapy Combinations Continue to Shine
Chinese-developed immune checkpoint inhibitors, represented by toripalimab, are accelerating the transition of innovative therapies in urologic oncology from followers to global contributors. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Chinese innovation was not only featured in oral presentations but also prominently showcased in the poster halls. Toripalimab combined with 9MW2821 demonstrated…
-
Global First Ultra-Remote Radical Nephrectomy with Inferior Vena Cava Tumor Thrombectomy (Level III Thrombus) Successfully Performed by Prof. Xuepei Zhang’s Team
From June 3 to 5, 2026, the Challenges in Laparoscopy, Robotics & AI 2026 (CILR-AI 2026) conference was held in Rome, Italy, bringing together leading experts from Europe, North America, Asia, and beyond.
-
ASCO Spotlight | Prof. Jun Guo & Prof. Shilpa Gupta: 3.5-Year EV-302 Follow-Up Highlights the Curative Potential of EV + Pembrolizumab in Advanced Urothelial Carcinoma
The 2026 ASCO Annual Meeting has officially opened, bringing a wealth of landmark studies in genitourinary oncology and providing new momentum for precision treatment in urothelial carcinoma (UC). To promote standardized and precision-based management of urologic cancers in China, the Hainan Lecheng Hongyuan Medical Technology Innovation and Development Research Institute launched the “Academic Exchange Program…
-
ASCO Voice of China | Prof. Yijun Shen Presents Oral Abstract on SHR-A2102 Combination Therapy: A New Breakthrough in Perioperative Treatment for MIBC
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting has once again brought together the latest breakthroughs in cancer research and drug development from around the world. As the largest and most influential oncology conference globally, every oral presentation represents a major advance in clinical practice and translational research.
-
ASCO Voices from China | Professor Wang He and Professor Wenlong Zhong: cCR Rate Reaches 82.35%—Disitamab Vedotin-Based Perioperative Therapy Redefines the Bladder Preservation Paradigm
Although radical cystectomy remains the standard treatment for muscle-invasive bladder cancer (MIBC) and high-risk non-muscle-invasive bladder cancer (NMIBC) that is unresponsive to Bacillus Calmette-Guérin (BCG) therapy, many patients are either unsuitable for or unwilling to undergo radical cystectomy because of underlying comorbidities and the potential impact on quality of life. Consequently, there is an urgent…
-
ASCO Voices from China | Professor Hao Zeng and Dr. Junru Chen: ORR Reaches 51.6% and DCR 96.8%—Bispecific Antibody Plus Targeted Therapy Opens a New Treatment Avenue for nccRCC
In recent years, immunotherapy-based combination regimens have transformed the treatment landscape of renal cell carcinoma (RCC) and have become standard first-line options for advanced clear cell renal cell carcinoma (ccRCC). However, therapeutic progress in non-clear cell renal cell carcinoma (nccRCC) has remained limited. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the…
-
ASCO Spotlight | Professor Thomas Powles: Long-Term EV-302 Follow-Up Delivers Impressive Results, Bringing the Hope of Cure to Patients with Advanced Urothelial Carcinoma
ASCO 2026 has officially opened, featuring 518 major studies in genitourinary oncology, with antibody-drug conjugates (ADCs) emerging as one of the most exciting areas of progress. Among them, enfortumab vedotin (EV), a Nectin-4-targeting ADC, was the subject of 36 presentations, continuing to drive transformative changes in the treatment landscape of urothelial carcinoma (UC).
-
Tracing ASCO | Professor Yijun Shen: China-Developed Immunotherapy–ADC Combinations Take the ASCO Stage, Reshaping the Future of Genitourinary Cancer Treatment
The combination of immune checkpoint inhibitors and antibody-drug conjugates (ADCs) is rapidly expanding from the first-line treatment of advanced disease into the perioperative setting, fundamentally reshaping the treatment landscape of urothelial carcinoma (UC). As global research momentum continues to accelerate, Chinese-developed immunotherapy–ADC combinations are emerging as important contributors to this evolving field.
Connecting Medical Expertise through Media